Eisas

Japanese pharmaceutical company specializing in CNS and oncology drugs, known for Alzheimer's treatments like Aricept and Leqembi in global markets.

Pass

Agentic behavior and permission review.

Pattern checks against bundled files.

Multi-engine malware detections and file reputation.

openclaw skills install eisas

Eisai — Advancing Brain Health

1941: Eisai Co., Ltd. founded in Tokyo by Takejiro Ueno
1960s-70s: Expands into prescription pharmaceuticals
1990s: Establishes US subsidiary, begins global expansion
2010: Aricept (donepezil) becomes one of the best-selling Alzheimer's drugs ever
2019: Lecanemab (Leqembi) receives FDA breakthrough therapy designation for Alzheimer's
2023: Leqembi receives full FDA approval — landmark in Alzheimer's treatment
2024: Expanding neuroscience pipeline with new molecular entities

Alzheimer's leadership: Leqembi positions Eisai at the forefront of Alzheimer's treatment
R&D focus: 20%+ of revenue invested in R&D — above industry average
hPHC philosophy: "human health care" philosophy drives patient-centric drug development
Strategic partnerships: Biogen collaboration shares risk and accelerates development

Revenue: ¥800B+ (~$5.5B) annually
Leqembi potential: Blockbuster status expected with $5B+ peak sales estimate
R&D spend: ¥160B+ annually
Employees: 11,000+ across 30+ countries

Eisai's name comes from "Eisai" (衛佐), the founder's belief that medicine should "aid and protect" (衛る佐ける) people's health — the company motto is "ihl" (integrative innovation for health and life)
The Aricept-Lecanemab journey spans 30+ years of Alzheimer's research at Eisai, making it one of the longest and most committed pharma efforts in the disease